Dr. Erba Discusses Molecular Monitoring for CML

Harry Erba, MD, PhD
Published: Tuesday, May 08, 2012

Harry Erba, MD, PhD, associate professor, Department of Internal Medicine, University of Michigan Health System, notes that molecular monitoring in patients with chronic myeloid leukemia (CML) allows the physician to assess the bone marrow in a non-invasive way, once the tumor has entered into complete cytogenetic remission.

Large controlled international studies have used polymerase chain reaction analyses to demonstrate that a major molecular response (MMR) that is achieved before 12 months, following the introduction of therapy, is an adequate surrogate marker for progression-free survival. According to the international standards, MMR corresponds to a 1000 fold reduction in the BCR-ABL transcript, which greatly diminishes tumor growth.

Erba believes the greatest benefit of molecular monitoring is to know exactly when a patient has developed resistance to treatment using a peripheral blood testing.

SELECTED
LANGUAGE
Harry Erba, MD, PhD, associate professor, Department of Internal Medicine, University of Michigan Health System, notes that molecular monitoring in patients with chronic myeloid leukemia (CML) allows the physician to assess the bone marrow in a non-invasive way, once the tumor has entered into complete cytogenetic remission.

Large controlled international studies have used polymerase chain reaction analyses to demonstrate that a major molecular response (MMR) that is achieved before 12 months, following the introduction of therapy, is an adequate surrogate marker for progression-free survival. According to the international standards, MMR corresponds to a 1000 fold reduction in the BCR-ABL transcript, which greatly diminishes tumor growth.

Erba believes the greatest benefit of molecular monitoring is to know exactly when a patient has developed resistance to treatment using a peripheral blood testing.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x